(Q36718446)

15 August 2017

1 reference

title

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide (English)

1 reference

15 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

André J Scheen

1

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Clinical Pharmacokinetics

15 August 2017

published in

1 reference

15 August 2017

volume

46

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

93-108

1 reference

Pathophysiology of insulin secretion

15 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746020-00001

Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746020-00001

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

21 January 2018

1 reference

12 December 2020

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

12 December 2020

Influence of diet and nutritional status on drug metabolism

1 reference

12 December 2020

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide

1 reference

12 December 2020

H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine

1 reference

12 December 2020

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

12 December 2020

Nutrition principles and recommendations in diabetes.

1 reference

12 December 2020

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

1 reference

12 December 2020

The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma

1 reference

12 December 2020

Food-drug interactions

1 reference

12 December 2020

Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent

1 reference

12 December 2020

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

1 reference

12 December 2020

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide

1 reference

12 December 2020

Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance

1 reference

12 December 2020

Purification by p-aminobenzoic acid (PABA)-affinity chromatography and the functional reconstitution of the nateglinide/H+ cotransport system in the rat intestinal brush-border membrane

1 reference

12 December 2020

Drug interaction studies with repaglinide: repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics

1 reference

12 December 2020

Effect of diet and nutrition on the expression of cytochromes P450.

1 reference

12 December 2020

Oral Antidiabetic Agents

1 reference

12 December 2020

Standards of medical care in diabetes--2006

1 reference

12 December 2020

The role of sulphonylureas in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis

1 reference

12 December 2020

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus

1 reference

12 December 2020

Pharmacokinetics and metabolism of nateglinide in humans.

1 reference

12 December 2020

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

1 reference

12 December 2020

A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.

1 reference

12 December 2020

Rifampin decreases the plasma concentrations and effects of repaglinide

1 reference

12 December 2020

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

1 reference

12 December 2020

1 reference

12 December 2020

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

1 reference

12 December 2020

Oral antidiabetic agents. A guide to selection

1 reference

12 December 2020

Cyclosporine markedly raises the plasma concentrations of repaglinide

1 reference

12 December 2020

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

1 reference

12 December 2020

Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

1 reference

12 December 2020

Repaglinide in the management of new-onset diabetes mellitus after renal transplantation

1 reference

12 December 2020

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

1 reference

12 December 2020

Substrate specificity of the nateglinide/H(+) cotransport system for phenolic acids

1 reference

12 December 2020

Intestinal uptake of nateglinide by an intestinal fluorescein transporter

1 reference

12 December 2020

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

1 reference

12 December 2020

Influence of dietary components on the gastrointestinal metabolism and transport of drugs

1 reference

12 December 2020

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

1 reference

12 December 2020

Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance

1 reference

12 December 2020

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

1 reference

12 December 2020

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

12 December 2020

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

1 reference

12 December 2020

Clinical pharmacokinetics of metformin

1 reference

12 December 2020

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

1 reference

12 December 2020

Food-drug interaction: grapefruit juice augments drug bioavailability--mechanism, extent and relevance

1 reference

12 December 2020

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

1 reference

12 December 2020

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

1 reference

12 December 2020

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

1 reference

12 December 2020

Insulinotropic meglitinide analogues

1 reference

12 December 2020

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

1 reference

12 December 2020

Ionization, lipophilicity and solubility properties of repaglinide

1 reference

12 December 2020

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus

1 reference

12 December 2020

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

1 reference

12 December 2020

Repaglinide in combination therapy

1 reference

12 December 2020

Food-drug interaction between ferulic acid and nateglinide involving the fluorescein/H+ cotransport system

1 reference

12 December 2020

Cyclosporine A increases plasma concentrations and effects of repaglinide.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

12 December 2020

No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers

1 reference

12 December 2020

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

1 reference

12 December 2020

Pharmacokinetic interactions with thiazolidinediones

1 reference

12 December 2020

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

1 reference

12 December 2020

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

1 reference

12 December 2020

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

1 reference

12 December 2020

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers

1 reference

12 December 2020

Hepatotoxicity with thiazolidinediones: is it a class effect?

1 reference

12 December 2020

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

12 December 2020

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes

1 reference

12 December 2020

Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant?

1 reference

12 December 2020

Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update

1 reference

12 December 2020

10.2165/00003088-200746020-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1009678445

0 references

1 reference